... continued from page 75.
A first-of-a-kind national clinical trial called DELFI-L101, sponsored by the Johns Hopkins University spin-out Delfi Diagnostics, is evaluating a test based on the DELFI technology in 1,700 participants in the U.S., including healthy participants, individuals with lung cancers and individuals with other cancers. The group would like to further study DELFI in other types of cancers.
Other scientists who contributed to the work include Stephen Cristiano, Jamie E. Medina, Jillian Phallen, Daniel Bruhm, Noushin Niknafs, Leonardo Ferreira, Vilmos Adleff, Jia Yuee Ciao, Alessandro Leal, Michael Noe, James White, Adith S. Arun, Carolyn Hruban, Akshaya V. Annapragada, Patrick M. Forde, Valsamo Anagnostou and Julie R. Brahmer of Johns Hopkins. Additional authors were from Herlev and Gentofte Hospital and Bispebjerg Hospital in Copenhagen; Aarhus University Hospital in Aarhus, Denmark; Herning Regional Hospital in Herning, Denmark; the Netherlands Cancer Institute in Amsterdam; Delfi Diagnostics; and Hvidovre Hospital in Hvidovre, Denmark.
The work was supported in part by the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; a Stand Up to Cancer /INTIME Lung Cancer Interception Dream Team grant; Stand Up to Cancer-Dutch Cancer Society International Translational Cancer Research Dream Team Grant (SU2C-AACR-DT1415); the Gray Foundation; the Commonwealth Foundation; the Mark Foundation for Cancer Research; the Lundbeck Foundation; the Cole Foundation; an unrestricted grant from Roche Denmark; a research grant from Delfi Diagnostics; and National Institutes of Health grants CA121113, CA006973, CA233259 and 1T32GM136577.
Mathios, Cristiano, Phallen, Leal, Adleff, Scharpf and Velculescu are inventors on patent applications submitted by Johns Hopkins University related to cell-free DNA for cancer detection. Cristiano, Phallen, Leal, Adleff and Scharpf are founders of Delfi Diagnostics, and Adleff and Scharpf are consultants for this organization. Velculescu is a founder of Delfi Diagnostics and of Personal Genome Diagnostics, serves on the board of directors and as a consultant for both organizations, and owns Delfi Diagnostics and Personal Genome Diagnostics stock, which are subject to certain restrictions under university policy. The Johns Hopkins University owns equity in Delfi Diagnostics and Personal Genome Diagnostics. Additionally, Velculescu is an adviser to Bristol-Myers Squibb, Genentech, and Takeda Pharmaceuticals. The terms of these arrangements are managed by The Johns Hopkins University in accordance with its conflict of interest policies.
Media Contacts
Valerie Mehl, 410-614-2916, [email protected]
Amy Mone, 410-614-2915, [email protected]
Topics
Cancer
Departments
The Sidney Kimmel Comprehensive Cancer Center
###
76